Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab + Pembrolizumab in Stage IV NSCLC
NCT02451930Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of necitumumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With Dose Limiting Toxicities and Objective Response Rate up to 16 months. Started Sep 2015; status: completed.
02
Drugs
necitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02451930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451930.